Carl Coeck

2.9k total citations · 2 hit papers
25 papers, 1.7k citations indexed

About

Carl Coeck is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Carl Coeck has authored 25 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 9 papers in Physiology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Carl Coeck's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (20 papers), Sarcoidosis and Beryllium Toxicity Research (6 papers) and Systemic Sclerosis and Related Diseases (5 papers). Carl Coeck is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (20 papers), Sarcoidosis and Beryllium Toxicity Research (6 papers) and Systemic Sclerosis and Related Diseases (5 papers). Carl Coeck collaborates with scholars based in Germany, United States and France. Carl Coeck's co-authors include Luca Richeldi, Manuel Quaresma, Vincent Cottin, Kevin K. Brown, Rozsa Schlenker‐Herceg, Susanne Stowasser, Martin Kolb, Anand Devaraj, Yoshikazu Inoue and Simon Walsh and has published in prestigious journals such as New England Journal of Medicine, CHEST Journal and Annals of the Rheumatic Diseases.

In The Last Decade

Carl Coeck

23 papers receiving 1.7k citations

Hit Papers

Nintedanib in Progressive Fibrosing Interstitial Lung Dis... 2019 2026 2021 2023 2019 2025 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
    2019 1.3k citations Kevin R. Flaherty, Athol U. Wells et al. New England Journal of Medicine profile →
  2. Nerandomilast in Patients with Progressive Pulmonary Fibrosis
    2025 19 citations Toby M. Maher, Shervin Assassi et al. New England Journal of Medicine profile →

Peers

Carl Coeck
Thomas Haeufel Germany
Margarida Alves Germany
In Sang Jeon South Korea
Takefumi Nikaido Japan
Laïla Chbani Morocco
Kotaro Kumano Japan
Masatoshi Kida United States
Kakuhiro Yamaguchi Japan
Yukiko Miura Japan
Terence K. Trow United States
Thomas Haeufel Germany
Carl Coeck
Citations per year, relative to Carl Coeck Carl Coeck (= 1×) peers Thomas Haeufel

Countries citing papers authored by Carl Coeck

Since Specialization
Citations

This map shows the geographic impact of Carl Coeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Coeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Coeck more than expected).

Fields of papers citing papers by Carl Coeck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl Coeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Coeck. The network helps show where Carl Coeck may publish in the future.

Co-authorship network of co-authors of Carl Coeck

This figure shows the co-authorship network connecting the top 25 collaborators of Carl Coeck. A scholar is included among the top collaborators of Carl Coeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl Coeck. Carl Coeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maher, Toby M., Shervin Assassi, Arata Azuma, et al.. (2025). Nerandomilast in Patients with Progressive Pulmonary Fibrosis. New England Journal of Medicine. 392(22). 2203–2214. 19 indexed citations breakdown →
2.
Wuyts, Wim, Francesco Bonella, Nazia Chaudhuri, et al.. (2025). Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON. Lung. 203(1). 25–25. 3 indexed citations
3.
Hart, Simon P., Robert J. Kaner, Tejaswini Kulkarni, et al.. (2024). Objective measurement of cough in pulmonary fibrosis: a cohort study – ImpaCT. ERJ Open Research. 10(5). 310–2024.
4.
Maher, Toby M., Arata Azuma, Vincent Cottin, et al.. (2023). POS1329 DESIGN OF A PHASE III, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF BI 1015550 IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE. Annals of the Rheumatic Diseases. 82. 1014–1015.
5.
Maher, Toby M., Shervin Assassi, Arata Azuma, et al.. (2023). Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Respiratory Research. 10(1). e001580–e001580. 16 indexed citations
6.
Inoue, Yoshikazu, Athol U. Wells, Jin Woo Song, et al.. (2023). Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial. Respirology. 28(5). 465–474. 4 indexed citations
7.
Cottin, Vincent, Fernando J. Martinez, Gísli Jenkins, et al.. (2022). Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial. Respiratory Research. 23(1). 85–85. 32 indexed citations
8.
Cottin, Vincent, Luca Richeldi, Iván O. Rosas, et al.. (2021). Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respiratory Research. 22(1). 84–84. 39 indexed citations
9.
Aringer, Martin, Janet Pope, Clive Kelly, et al.. (2020). THU0189 EFFICACY AND SAFETY OF NINTEDANIB IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASE TREATED WITH DMARDS AND/OR GLUCOCORTICOIDS AT BASELINE. Annals of the Rheumatic Diseases. 79. 313–314. 3 indexed citations
10.
Koschel, Dirk, Vincent Cottin, Anand Devaraj, et al.. (2020). Nintedanib in patients with chronic fibrosing Interstitial lung diseases with progressive phenotype: the INBUILD trial*. Pneumologie. 2 indexed citations
11.
Volkmann, Elizabeth R., I. Castellví, Sindhu R. Johnson, et al.. (2020). SAT0157 NINTEDANIB DOSE ADJUSTMENTS AND ADVERSE EVENTS IN PATIENTS WITH PROGRESSIVE AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES IN THE INBUILD TRIAL. Annals of the Rheumatic Diseases. 79. 1019–1019. 1 indexed citations
12.
Flaherty, Kevin R., Athol U. Wells, Vincent Cottin, et al.. (2019). Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine. 381(18). 1718–1727. 1333 indexed citations breakdown →
13.
Flaherty, Kevin R., Athol U. Wells, Vincent Cottin, et al.. (2019). Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial. RCT1881–RCT1881. 4 indexed citations
14.
Distler, Oliver, Kevin K. Brown, Jörg H. W. Distler, et al.. (2017). Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).. PubMed. 35 Suppl 106(4). 75–81. 59 indexed citations
15.
Wind, Sven, et al.. (2017). FRI0411 Coadministration of bosentan has no effect on the pharmacokinetics of nintedanib. Annals of the Rheumatic Diseases. 76. 642–643. 1 indexed citations
16.
Corte, Tamera J., Francesco Bonella, Bruno Crestani, et al.. (2015). Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respiratory Research. 16(1). 116–116. 128 indexed citations
17.
18.
Crestani, Bruno, Takashi Ogura, Carl Coeck, et al.. (2015). Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON). OA4495–OA4495. 7 indexed citations
19.
Notteboom, Theo, et al.. (1997). Containerization and the competitive potential of upstream urban ports in Europe. Maritime Policy & Management. 24(3). 285–289. 17 indexed citations
20.
Slabbynck, Hans, et al.. (1993). Dyspnea, Fever, and Eosinophilia. CHEST Journal. 104(2). 585–586. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Haeufel Breakdown of academic impact, for papers by Margarida Alves Breakdown of academic impact, for papers by In Sang Jeon Breakdown of academic impact, for papers by Takefumi Nikaido Breakdown of academic impact, for papers by Laïla Chbani Breakdown of academic impact, for papers by Kotaro Kumano Breakdown of academic impact, for papers by Masatoshi Kida Breakdown of academic impact, for papers by Kakuhiro Yamaguchi Breakdown of academic impact, for papers by Yukiko Miura Breakdown of academic impact, for papers by Terence K. Trow
Rankless by CCL
2026